R&D Rare Disease R&D: one step forward, but a long road ahead With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.
News GSK plans $800m US manufacturing investment GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.